Viridian Therapeutics announces first patient enrolled in THRIVE Phase 3 trial

Viridian Therapeutics announced that the first patient has been enrolled in its THRIVE Phase 3 trial evaluating the efficacy and safety of the investigational agent VRDN-001 in patients with active thyroid eye disease, TED. The global THRIVE Phase 3 trial will be conducted in approximately 50 centers across North America and Europe. "We are pleased to enroll the first patient in the THRIVE trial, which is designed to confirm the compelling early results we’ve seen in TED patients," said Jonathan Violin, Ph.D., President and Chief Executive Officer of Viridian Therapeutics. "The study is a significant milestone for Viridian, and reinforces our commitment to the TED community. It is an important and meaningful step in our efforts to provide new and improved treatment options to patients with TED."